DE69819925T2 - Kontrastverstärktes Diagnosebildererzeugungsverfahren zur Überwachung von therapeutischen Eingriffen - Google Patents

Kontrastverstärktes Diagnosebildererzeugungsverfahren zur Überwachung von therapeutischen Eingriffen Download PDF

Info

Publication number
DE69819925T2
DE69819925T2 DE69819925T DE69819925T DE69819925T2 DE 69819925 T2 DE69819925 T2 DE 69819925T2 DE 69819925 T DE69819925 T DE 69819925T DE 69819925 T DE69819925 T DE 69819925T DE 69819925 T2 DE69819925 T2 DE 69819925T2
Authority
DE
Germany
Prior art keywords
tissue
use according
contrast
contrast agent
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69819925T
Other languages
German (de)
English (en)
Other versions
DE69819925D1 (de
Inventor
B. Randall LAUFFER
O. Stephen DUNHAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epix Pharmaceuticals Inc
Original Assignee
Epix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Pharmaceuticals Inc filed Critical Epix Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69819925D1 publication Critical patent/DE69819925D1/de
Publication of DE69819925T2 publication Critical patent/DE69819925T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052Small organic molecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Transforming Light Signals Into Electric Signals (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
DE69819925T 1997-10-02 1998-09-24 Kontrastverstärktes Diagnosebildererzeugungsverfahren zur Überwachung von therapeutischen Eingriffen Expired - Lifetime DE69819925T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94298997A 1997-10-02 1997-10-02
US942989 1997-10-02
PCT/US1998/020182 WO1999017809A2 (fr) 1997-10-02 1998-09-24 Methode d'imagerie diagnostique amelioree par des agents de contraste dans le controle des therapies d'intervention

Publications (2)

Publication Number Publication Date
DE69819925D1 DE69819925D1 (de) 2003-12-24
DE69819925T2 true DE69819925T2 (de) 2004-09-02

Family

ID=25478927

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69819925T Expired - Lifetime DE69819925T2 (de) 1997-10-02 1998-09-24 Kontrastverstärktes Diagnosebildererzeugungsverfahren zur Überwachung von therapeutischen Eingriffen

Country Status (20)

Country Link
US (2) US6861045B1 (fr)
EP (1) EP1019094B1 (fr)
JP (2) JP2001518523A (fr)
KR (1) KR20010030854A (fr)
AT (1) ATE254479T1 (fr)
AU (1) AU742438C (fr)
BR (1) BR9812716A (fr)
CA (1) CA2303426C (fr)
DE (1) DE69819925T2 (fr)
DK (1) DK1019094T3 (fr)
ES (1) ES2206996T3 (fr)
HK (1) HK1030744A1 (fr)
HU (1) HUP0101245A3 (fr)
IL (1) IL134985A0 (fr)
IS (1) IS2041B (fr)
NO (1) NO321966B1 (fr)
NZ (1) NZ503402A (fr)
PT (1) PT1019094E (fr)
SK (1) SK4842000A3 (fr)
WO (1) WO1999017809A2 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495118B1 (en) 1997-09-26 2002-12-17 Schering Aktiengesellschaft Lipophilic metal complexes for necrosis and infarction imaging
EP1019094B1 (fr) * 1997-10-02 2003-11-19 Epix Medical, Inc. Methode d'imagerie diagnostique amelioree par des agents de contraste dans le controle des therapies d'intervention
US6167297A (en) * 1999-05-05 2000-12-26 Benaron; David A. Detecting, localizing, and targeting internal sites in vivo using optical contrast agents
AU1791501A (en) 1999-11-22 2001-06-04 Epix Medical, Inc. Imaging sexual response
EP1251876A2 (fr) * 2000-01-22 2002-10-30 Epix Medical, Inc. Imagerie par resonance magnetique avec utilisation d'agents de contraste bioactives par clivage enzymatique
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
EP1423136A4 (fr) * 2001-08-10 2007-07-25 Epix Pharm Inc Conjugues de polypeptides ayant des demi-vies de circulation accrues
EP1587944A4 (fr) 2002-03-01 2007-03-21 Dyax Corp Peptides de liaison kdr et vegf/kdr et leur utilisation a des fins diagnostiques et therapeutiques
ES2506142T3 (es) 2002-03-01 2014-10-13 Dyax Corp. Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
ES2396368T3 (es) 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
US20050064045A1 (en) * 2003-09-18 2005-03-24 Sheng-Ping Zhong Injectable therapeutic formulations
EP1747026A1 (fr) * 2004-05-18 2007-01-31 Siemens Aktiengesellschaft Agents de contraste biomoleculaires de controle therapeutique dans une radiotherapie avec faisceau d'ions ou de protons
US7585492B2 (en) 2004-05-18 2009-09-08 Siemens Aktiengesellschaft Biomolecular contrast agents for therapy success and dose monitoring in radiation therapy with proton or ion beams
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
EP1957996A1 (fr) * 2005-11-29 2008-08-20 Koninklijke Philips Electronics N.V. Distinction d'agents de contraste lies et non lies au moyen de la resonance magnetique
WO2007073792A1 (fr) * 2005-12-19 2007-07-05 Bayer Schering Pharma Aktiengesellschaft Procede de fabrication de 4,4-diphenylcyclohexanol
KR101336505B1 (ko) 2006-08-17 2013-12-05 에픽스 파마슈티칼스, 인코포레이티드 림프계의 영상화 방법
DE102006049821A1 (de) 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung
US20100092389A1 (en) * 2008-10-10 2010-04-15 The General Hospital Corporation Detection of atherosclerosis using indocyanine green
WO2010048708A1 (fr) * 2008-10-27 2010-05-06 The University Of Western Ontario Système et procédé pour imagerie par résonance magnétique
WO2010121133A2 (fr) 2009-04-17 2010-10-21 The General Hospital Corporation Imagerie multimodale de fibrine
KR20110139274A (ko) 2009-03-19 2011-12-28 와이어쓰 엘엘씨 [2-(8,9-다이옥소-2,6-다이아자바이사이클로[5.2.0]논-1(7)-엔-2-일)에틸]포스폰산 및 이의 전구체의 제조 방법
RU2559930C2 (ru) 2010-02-02 2015-08-20 Конинклейке Филипс Электроникс Н.В. Формирование функциональных изображений
TW201514188A (zh) 2013-03-13 2015-04-16 Lantheus Medical Imaging Inc 製備釓磷維塞三鈉單水合物之方法
US11160454B2 (en) * 2013-04-08 2021-11-02 Sunnybrook Research Institute System and method for imaging biomarkers indicative of cardiac thermal ablation lesions
JP2015087167A (ja) * 2013-10-29 2015-05-07 キヤノン株式会社 画像処理方法、画像処理システム
WO2015089505A2 (fr) 2013-12-13 2015-06-18 The Trustees Of The University Of Pennsylvania Sonde d'ablation coaxiale, et procédé et système de surveillance en temps réel d'une thérapie ablative
US20150344523A1 (en) 2014-05-05 2015-12-03 California Institute Of Technology Mutant akt-specific capture agents, compositions, and methods of using and making
WO2015196208A2 (fr) 2014-06-20 2015-12-23 The General Hospital Corporation Sondes d'imagerie ciblées sur le collagène
WO2016149404A1 (fr) 2015-03-16 2016-09-22 California Institute Of Technology Agents de capture spécifiques de la neurotoxine botulique, compositions et méthodes d'utilisation et de préparation associées
CN115112898A (zh) 2015-07-15 2022-09-27 加州理工学院 Il-17f-特异性捕获剂、组合物以及使用和制造的方法
US10383590B2 (en) 2015-09-28 2019-08-20 General Electric Company Methods and systems for adaptive scan control
EP3519425B1 (fr) 2016-09-29 2024-02-28 Indi Molecular, Inc. Compositions pour la détection, l'inhibition et l'imagerie de l'indoléamine 2,3-dioxygénase 1 (ido1) et leurs méthodes de production et d'utilisation
WO2018085375A1 (fr) 2016-11-01 2018-05-11 Ohio State Innovation Foundation Procédés d'iodation de biomolécules
EP3638687A1 (fr) 2017-06-15 2020-04-22 Indi Molecular, Inc. Agents de capture spécifiques d'il-17f et il-17a, compositions et procédés d'utilisation et de production
US20190370956A1 (en) 2018-05-30 2019-12-05 General Electric Company Contrast imaging system and method
US11919972B2 (en) 2018-11-02 2024-03-05 Regeneron Pharmaceuticals, Inc. Peptide libraries with non-canonical amino acids
US11638764B2 (en) 2018-11-08 2023-05-02 Indi Molecular, Inc. Theranostic capture agents, compositions, and methods of using and making
US11414460B2 (en) 2019-07-19 2022-08-16 Institute For Systems Biology KRAS-specific capture agents, compositions, and methods of making and using
WO2022098743A1 (fr) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imagerie et procédés thérapeutiques ciblant le récepteur 1 de folate (folr1)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250285A (en) 1985-05-08 1993-10-05 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic NMR imaging
US5094848A (en) 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
IT1269839B (it) 1994-05-26 1997-04-15 Bracco Spa Coniugati di acidi biliari, loro derivati con complessi metallici e relativi usi
TW319763B (fr) * 1995-02-01 1997-11-11 Epix Medical Inc
CA2539215A1 (fr) 1995-02-01 1996-08-08 Epix Pharmaceuticals, Inc. Agents de contraste pour imagerie diagnostique presentant une retention prolongee dans le sang
DE19529512C2 (de) 1995-08-10 2000-11-23 Siemens Ag Verfahren zur Phasenkontrast-MR-Angiographie und Anordnung zur Durchführung des Verfahrens
DE19543785A1 (de) 1995-11-24 1997-05-28 Philips Patentverwaltung MR-Verfahren und Anordnung zur Durchführung des Verfahrens
CA2247620A1 (fr) * 1996-04-01 1997-10-09 Epix Medical, Inc. Agents de contraste bioactives destines a l'imagerie
IT1283650B1 (it) 1996-08-02 1998-04-23 Bracco Spa Chelati paramagnetici ad alta relassivita' in siero
US5919967A (en) 1997-04-11 1999-07-06 Epix Medical, Inc. Process for synthesizing phosphodiesters
EP1019094B1 (fr) * 1997-10-02 2003-11-19 Epix Medical, Inc. Methode d'imagerie diagnostique amelioree par des agents de contraste dans le controle des therapies d'intervention
IT1304501B1 (it) 1998-12-23 2001-03-19 Bracco Spa Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza

Also Published As

Publication number Publication date
EP1019094A2 (fr) 2000-07-19
HUP0101245A2 (hu) 2001-08-28
US6861045B1 (en) 2005-03-01
EP1019094B1 (fr) 2003-11-19
HUP0101245A3 (en) 2003-10-28
NZ503402A (en) 2002-03-01
JP2006077020A (ja) 2006-03-23
DK1019094T3 (da) 2004-02-16
IS5399A (is) 2000-03-10
ES2206996T3 (es) 2004-05-16
CA2303426A1 (fr) 1999-04-15
NO321966B1 (no) 2006-07-31
AU9668698A (en) 1999-04-27
IS2041B (is) 2005-09-15
WO1999017809A2 (fr) 1999-04-15
PT1019094E (pt) 2004-03-31
AU742438B2 (en) 2002-01-03
ATE254479T1 (de) 2003-12-15
WO1999017809A3 (fr) 1999-05-20
US20050118103A1 (en) 2005-06-02
NO20001707L (no) 2000-05-31
JP2001518523A (ja) 2001-10-16
IL134985A0 (en) 2001-05-20
AU742438C (en) 2003-05-22
US7175829B2 (en) 2007-02-13
BR9812716A (pt) 2000-08-22
HK1030744A1 (en) 2001-05-18
DE69819925D1 (de) 2003-12-24
NO20001707D0 (no) 2000-04-03
CA2303426C (fr) 2008-09-23
SK4842000A3 (en) 2000-11-07
KR20010030854A (ko) 2001-04-16

Similar Documents

Publication Publication Date Title
DE69819925T2 (de) Kontrastverstärktes Diagnosebildererzeugungsverfahren zur Überwachung von therapeutischen Eingriffen
DE69636635T2 (de) Kontrastmittel für diagnostische bildgebung mit verlängerter verweilzeit im blut
DE3650572T3 (de) Kontrastmittel zur darstellung des leber-gallensystems mittels nmr-kontrastmittel
JP2007528854A (ja) 細胞への物質送達の遠隔検出
AU3944893A (en) Methods and compositions for magnetic resonance imaging
ES2393780T3 (es) Procedimiento de toma de imágenes por resonancia magnética y compuestos para uso en el procedimiento
JP2001518454A (ja) 壊死および梗塞のイメージングのための親油性金属錯体
EP0948361B1 (fr) Agents d'imagerie du pool sanguin par resonance magnetique
EP0673655A1 (fr) Milieu de contraste destine a l'imagerie par resonance magnetique et procede de diagnostic
US5869026A (en) Tripodal carboxamide ligands for MRI contrast agents
MXPA00002869A (en) Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
CZ20001189A3 (cs) Diagnostické činidlo pro monitorování intervenčních terapií
AU3138702A (en) Contrast-enhanced diagnostic imaging method for monitoring interventional therapies

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: EPIX PHARMACEUTICALS,INC.(N.D.GES.D.STAATES DELAWA

8327 Change in the person/name/address of the patent owner

Owner name: EPIX PHARMACEUTICALS, INC., LEXINGTON, MASS., US